Recent executive actions have accelerated federal cannabis rescheduling. In December 2025, an executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. April 2026 orders immediately transferred FDA-approved products and state-licensed medical marijuana to Schedule III while launching a streamlined administrative hearing on broader rescheduling. That hearing opened June 29, 2026, at DEA headquarters and concluded no later than July 15, 2026, allowing evidence and testimony on medical use, abuse potential, and dependence. Trader focus now centers on the administrative law judge’s post-hearing recommendation, any final rule issuance by the DEA or Attorney General, and potential legal challenges or procedural delays that could extend the timeline beyond late 2026.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$796,389 Vol.
Mar 31, 2026
September 30
14%
December 31
26%
$796,389 Vol.
September 30
$0 Vol.
14%
December 31
$186,818 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have accelerated federal cannabis rescheduling. In December 2025, an executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. April 2026 orders immediately transferred FDA-approved products and state-licensed medical marijuana to Schedule III while launching a streamlined administrative hearing on broader rescheduling. That hearing opened June 29, 2026, at DEA headquarters and concluded no later than July 15, 2026, allowing evidence and testimony on medical use, abuse potential, and dependence. Trader focus now centers on the administrative law judge’s post-hearing recommendation, any final rule issuance by the DEA or Attorney General, and potential legal challenges or procedural delays that could extend the timeline beyond late 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Pasar Dibuka: Feb 7, 2026, 5:04 PM ET
Volume
$796,389Tanggal Berakhir
Mar 31, 2026Pasar Dibuka
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have accelerated federal cannabis rescheduling. In December 2025, an executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. April 2026 orders immediately transferred FDA-approved products and state-licensed medical marijuana to Schedule III while launching a streamlined administrative hearing on broader rescheduling. That hearing opened June 29, 2026, at DEA headquarters and concluded no later than July 15, 2026, allowing evidence and testimony on medical use, abuse potential, and dependence. Trader focus now centers on the administrative law judge’s post-hearing recommendation, any final rule issuance by the DEA or Attorney General, and potential legal challenges or procedural delays that could extend the timeline beyond late 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$796,389Tanggal Berakhir
Mar 31, 2026Pasar Dibuka
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent executive actions have accelerated federal cannabis rescheduling. In December 2025, an executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. April 2026 orders immediately transferred FDA-approved products and state-licensed medical marijuana to Schedule III while launching a streamlined administrative hearing on broader rescheduling. That hearing opened June 29, 2026, at DEA headquarters and concluded no later than July 15, 2026, allowing evidence and testimony on medical use, abuse potential, and dependence. Trader focus now centers on the administrative law judge’s post-hearing recommendation, any final rule issuance by the DEA or Attorney General, and potential legal challenges or procedural delays that could extend the timeline beyond late 2026.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan